To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.

Last updated: May 14, 2025
Sponsor: Neumora Therapeutics, Inc.
Overall Status: Active - Not Recruiting

Phase

2

Condition

Depression

Treatment

NMRA-335140 80 mg

Placebo

Clinical Study ID

NCT06429722
NMRA-335140-202
  • Ages 18-65
  • All Genders

Study Summary

This is a randomized, double-blind, placebo-controlled pilot study aiming to evaluate the effects of NMRA-335140 on symptoms of major depression in adults with Bipolar (BP) II disorder. The study design consists of a Screening Period (up to 28 days), a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo), and a 6-week Safety Follow-up Period.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Have a primary Diagnostic and Statistical Manual of Mental Disorders Fifth EditionText Revised (DSM-5-TR) diagnosis of BP II disorder with a current major depressiveepisode (MDE), without psychotic features confirmed by Structured Clinical Interviewfor DSM 5 Disorders, Clinical Trials Version (SCID-5-CT) at screening (this may be afirst or recurrent episode).

  2. Participant's current MDE and lifetime history of hypomanic episodes must beconfirmed by independent assessment.

  3. The symptoms of the current MDE have been present for more than 4 weeks prior to theScreening Visit, but no longer than 12 months prior to the Screening Visit.

  4. Have a MADRS total score of 25 or higher at Screening and Baseline.

  5. A change in MADRS total score between Screening and Baseline of ≤20%.

Exclusion

Exclusion Criteria:

  1. Have failed 2 or more courses of antidepressant (adequate dose and duration, i.e.,minimum 6 weeks) or mood stabilizer/antipsychotic treatment (each or in combination)for treatment of depressive symptoms in the current MDE.

  2. Have currently or in the past year any of the following DSM-5-TR disorders: bipolarepisodes with mixed features (including the current MDE), bipolar II with rapidcycling pattern (4 or more distinct mood episodes during a 12-month period).Participants with comorbid generalized anxiety disorder, social anxiety disorder,simple phobias, panic disorder, for whom bipolar II MDE is considered the primarydiagnosis are not excluded.

  3. Have a lifetime diagnosis of bipolar I disorder (manic episode schizophrenia,schizoaffective disorder, schizophreniform disorder, anorexia nervosa, bulimianervosa, cluster B personality disorder, post-traumatic stress disorder (PTSD), orobsessive- compulsive disorder.

  4. Have moderate to severe substance or alcohol use disorder, per DSM-5-TR criteria,within the 12 months prior to screening (excluding nicotine).

  5. Are actively suicidal (e.g., any suicide attempts within the past 12 months) or areat serious suicidal risk as indicated by any current suicidal intent, including aplan, as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) (score of "YES" on suicidal ideation Item 4 or 5 within 3 months prior to Visit 1 [screening])and/or based on clinical evaluation by the Investigator; or are homicidal, in theopinion of the Investigator.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Study Design

Total Participants: 60
Treatment Group(s): 2
Primary Treatment: NMRA-335140 80 mg
Phase: 2
Study Start date:
May 13, 2024
Estimated Completion Date:
December 31, 2025

Connect with a study center

  • Neumora Investigator Site

    Phoenix, Arizona 85012
    United States

    Site Not Available

  • Neumora Investigator Site

    Little Rock, Arkansas 72211
    United States

    Site Not Available

  • Neumora Investigator Site

    Garden Grove, California 92845
    United States

    Site Not Available

  • Neumora Investigator Site

    Long Beach, California 90807
    United States

    Site Not Available

  • Neumora Investigator Site

    San Jose, California 95124
    United States

    Site Not Available

  • Neumora Investigator Site

    Torrance, California 90504
    United States

    Site Not Available

  • Neumora Investigator Site

    Gainesville, Florida 32607
    United States

    Site Not Available

  • Neumora Investigator Site

    Lauderhill, Florida 33161
    United States

    Site Not Available

  • Neumora Investigator Site

    Maitland, Florida 32751
    United States

    Site Not Available

  • Neumora Investigator Site

    Miami, Florida 33122
    United States

    Site Not Available

  • Neumora Investigator Site

    Miami Lakes, Florida 33016
    United States

    Site Not Available

  • Neumora Investigator Site

    Marietta, Georgia 30060
    United States

    Site Not Available

  • Neumora Investigator Site

    Savannah, Georgia 31405
    United States

    Site Not Available

  • Neumora Investigator Site

    Watertown, Massachusetts 02472
    United States

    Site Not Available

  • Neumora Investigator Site

    Flowood, Mississippi 39232
    United States

    Site Not Available

  • Neumora Investigator Site

    Marlton, New Jersey 08053
    United States

    Site Not Available

  • Neumora Investigator Site

    Princeton, New Jersey 08540
    United States

    Site Not Available

  • Neumora Investigator Site

    Toms River, New Jersey 08755
    United States

    Site Not Available

  • Neumora Investigator Site

    Brooklyn, New York 11229
    United States

    Site Not Available

  • Neumora Investigator Site

    Houston, Texas 77030
    United States

    Site Not Available

  • Neumora Investigator Site

    Bellevue, Washington 98007
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.